Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY24 Earnings Presentation
35 slides from Jubilant Ingrevia's earnings presentation, Nov 1, 2023
Slide 1: Investor Presentation
Investor Presentation November 2023 Jubilant Ingrevia Limited 1
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Table of Contents
Company Snapshot and Strategic Outlook - 04 Financial Highlights – Q2 & H1’FY24 - 11 Business Segments Overview - 16 Strategic Initiatives Update - 26 Table of Contents 3
Slide 4: Company Overview
Company Overview Jubilant Ingrevia Limited 4
Slide 5: Jubilant Bhartia Group – Snapshot
Jubilant Bhartia Group – Snapshot- Our Old Version Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Established presence in diversified sectors, e.g., Agro and Pharma Intermediates, CDMO, Therapeutics, Speciality Chemicals, Nutrition, Food Servi
Slide 6: Jubilant Ingrevia – Overview
Jubilant Ingrevia – Overview 40+ years of legacy in Chemicals space, started in 1978 2300+ people with strong leadership team with average 25+ years of experience in Chemicals space Network of 5 state of art manufacturing facilities and 3 R&D centres with 100+ scientists Company overview and presenc
Slide 7: Integrated Business Segments
Integrated Business Segments Jubilant Ingrevia Limited Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates • Pyridine & Picolines • Acetyls • Nutrition & Health Ingredients • Fine Chemicals • Specialty Ethanol • Agro Chemicals • Animal & Human Nutrition Health Solutions • Microbi
Slide 8: Strategic Outlook: Pillars of Future Growth
Strategic Outlook: Pillars of Future Growth Leading provider of innovative and sustainable solutions in life sciences space globally Customer Safety as Innovation Digitally-Enabled, Environmental People World-Class Centricity: Front and and Operations: , Social, and Focused: Staying relevant Center:
Slide 9: Company Snapshot
Company Snapshot 134+ Expertise in 35 technology products commercialized across platforms and multistep Catering to 1500+ customers product platforms i.e, Pyridine, chemistry With Top 10 customers Diketene, Acetyls, Nutrition and constituting 20% of business CDMO Geographical Mix Diverse Industry En
Slide 10: Executive Leadership Team
Executive Leadership Team Deepak Jain Chief Executive Officer & Managing Director 18 years of industry & Consulting experience Ambrish Dixit Chandan Singh Sumit Das Ashish Kumar Sinha President Co-CEO SVP – Nutrition & VP – Animal & Human Speciality Chemicals Chemical Intermediates Health Ingredient
Slide 11: Financial Highlights Q2 & H1 FY'24
Financial Highlights Q2 & H1 FY’24 11 Jubilant Ingrevia Limited
Slide 12: Chairmen's Message on Q2'FY24 Financial Results
Chairmen’s Message on Q2’FY24 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce stable business performance in Q2 & H1 of FY24, amidst the challenging market conditions. In the Agrochemical sector we have witnessed reduced volumes of the active
Slide 13: Key Highlights | Q2'FY24
Key Highlights | Q2’FY24 • Specialty and Nutrition share increased • Bio certification of several products Product to 53% in Q2FY24 vs. 43% in Q2FY23 through C-14 tests Green/ESG Portfolio mix • Higher share of CDMO, Fine chemicals • New initiative to increase renewable % and Nutrition products in p
Slide 14: Financial Results Overview | Consolidated
Financial Results Overview | Consolidated Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 Q-o-Q Y-o-Y H1'FY23 H1'FY24 Y-o-Y Total Revenue 1,304 1,075 1,020 -5% -22% 2,469 2,095 -18% Total EBITDA 160 125 126 1% -21% 311 251 -24% EBITDA Margin (%) 12.3% 11.6% 12.4% 12.6% 12.0% Profit After Tax 84 58 57 0% -32% 1
Slide 15: Key Ratios | As on 30th September 2023
Key Ratios| As on 30th September 2023 Particulars1 FY’2023 Q1'FY2024 Q2'FY2024 Net Debt 312 492 701 Net Debt to Equity 0.12x 0.18x 0.27x Net Debt to EBITDA 0.54x 0.89x 1.35x Working Captal to Turnover 17% 20% 23% • Increase in Net Debt mainly led by steady capex expenditure and higher working capita
Slide 16: Business Segments Overview
Business Segments Overview 16 Jubilant Ingrevia Limited
Slide 17: Market & Business Highlights | Speciality Chemicals
Market & Business Highlights | Speciality Chemicals Market Highlights • CDMO and Pharma end-use demand remained stable. • Overall market situation remained challenging in Agro Chemical end-use products. Continued De-stocking and China capacities lead to higher channel Inventory. • Muted demand due t
Slide 18: Business Segment Overview | Speciality Chemicals
Business Segment Overview | Speciality Chemicals 70+ Products (Pyridines & Picolines, Globally among Top 2 Globally lowest cost Serving 15 of top 20 Cyanopyridines, in (Pyridine+Beta); producer of Pyridine Global Pharma & 7 of Piperidines, Globally #1 in 18 offering significant top 10 Global Aminopy
Slide 19: Financials | Speciality Chemicals Segment
Financials | Speciality Chemicals Segment Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 Q-o-Q Y-o-Y H1'FY23 H1'FY24 Y-o-Y Segment Revenues 480 364 382 5% -21% 863 745 -16% % Contribution to Revenues 37% 34% 37% 35% 36% EBITDA 77 57 69 21% -11% 141 126 -12% % EBITDA Margins 16% 16% 18% 16% 17% % Contribution
Slide 20: Market & Business Highlights | Nutrition & Health Solutions
Market & Business Highlights | Nutrition & Health Solutions Market Highlights • Vitamin demand normalised after witnessing pent-up demand in Q1. • Downstream industries maintaining low stock level across regions due to continuous downward price movement in all the vitamins. Business Highlights • Nut
Slide 21: Business Segment Overview | Nutrition & Health Solutions
Business Segment Overview | Nutrition & Health Solutions Catering to Varied End Use Industries, ranging from, Personal 5 Nutrition Ingredients Care, Pharmaceuticals and Animal Feed & Global top 2 in Full Backward 18+ branded solutions Vitamin B3 Integration for Vitamin B3 via green Niainamide End Us
Slide 22: Financials | Nutrition & Health Solutions
Financials |Nutrition & Health Solutions Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 Q-o-Q Y-o-Y H1'FY23 H1'FY24 Y-o-Y Segment Revenues 114 202 162 -20% 43% 264 364 28% % Contribution to Revenues 9% 19% 16% 11% 17% EBITDA 14 17 19 11% 38% 32 36 9% % EBITDA Margins 12% 8% 12% 12% 10% % Contribution to EBITD
Slide 23: Market & Business Highlights | Chemical Intermediates
Market & Business Highlights | Chemical Intermediates Market Highlights • Muted demand across all the downstream industries for Agrochemicals and Paracetamol. • Industry is maintaining low inventory levels. • Acetic Acid price remained range-bound hovering between ~$400/MT to $500/MT. Business Highl
Slide 24: Business Segment Overview | Chemical Intermediates
Business Segment Overview | Chemical Intermediates Catering to Varied End Use Industries, most of these end use 9 Products Acetic Anhydride: having promising growth (Acetic Anhydride, Ethyl Globally No. 2 in Acetate ,Propionic Merchant Mkt Anhydride, Aldehydes, No.1 in India Speciality Alcohol, Esti
Slide 25: Financial Highlights | Chemical Intermediates
Financial Highlights | Chemical Intermediates Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 Q-o-Q Y-o-Y H1'FY23 H1'FY24 Y-o-Y Segment Revenues 710 509 476 -6% -33% 1,343 985 -13% % Contribution to Revenues 54% 47% 47% 54% 47% EBITDA 76 60 50 -16% -34% 153 110 -32% % EBITDA Margins 11% 12% 11% 11% 11% % Contr
Slide 26: Key Strategic Initiatives
Key Strategic Initiatives Jubilant Ingrevia Limited 26
Slide 27: Sustainability, RDT, Digitization – Key Strategic Initiatives
Key Strategic Initiatives • Conducted Biogenic Carbon Content study of our products through C-14 testing, two of the products received Sustainability 100% rating and several products are 80% and above. • Conducted Product Carbon Foot-printing (PCF) for majority of our products RDT • Setup a new stat
Slide 28: Sustainability
Sustainability Participated in S&P DJSI Assessment: Bharuch Nira Gajraula Global chemical industry's EHS initiative (Dec (Oct (Oct & Ethical framework towards safe chemicals • Achieved 95 percentile in the 2018) 2019) 2021) management and performance excellence Global Chemical Industry • Among the t
Slide 29: Key Technology Platforms
Research Development & Technology (RDT) Newly setup R&D facility at greater Noida, equipped with state of the art technology, with advanced fume hoods and analytical machines to ensure efficient synthesis and reaction monitoring in a safer environment. Key Highlights 35 Key technology platforms deve
Slide 30: Efficiencies through Multi Location Manufacturing & Operation Excellence
Efficiencies through Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India India Speciality Chemicals, Integrated facility for Nutrition & Health Samlaya, Gujarat, India Ambernat
Slide 31: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships
Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships Mission: To develop multi-stakeholder sustainable models to 1 Aspiring to touch the Lives Established Million bring about ‘social change’ involving knowledge generation through social initiatives in 2007 lives & sharing, ex
Slide 32: Annexure 1 - Income Statement | Consolidated
Annexure 1- Income Statement | Consolidated Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 QoQ YoY H1'FY23 H1'FY24 YoY Revenue from operations a) Sales/Income from operations 1299 1069 1011 -5% -22% 2458 2080 -15% b) Other operating income 5 6 9 39% 92% 11 15 38% Total revenue from operations 1304 1075 1020 -
Slide 33: Annexure II: Income Statement Segmental
Annexure II: Income Statement Segmental – Q1 & H1‘FY24 Particulars1 Q2'FY23 Q1'FY24 Q2'FY24 QoQ (%) YoY (%) H1'FY23 H1'FY24 YoY (%) Total Revenue from Operations 1,304 1,075 1,020 (5%) (22%) 2,469 2,095 (15%) Speciality Chemicals 480 364 382 5% (21%) 863 745 (14%) Nutrition & Health Solutions 114 20
Slide 34: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Jubilant Ingrevia Limited. Industrial customers with customised products and solut
Slide 35: Annexure III - Conference Call Details
Annexure III - Conference Call Details Diamond Pass Log-In Date : November 01st, 2023 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers,